Loading…
Reported covered position: Senior Advisor, Office of the Administrator, CMS; Director, Medicare Parts C and D Analysis Group, Office of Legislation, CMS.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OSSIUM HEALTH, INC. via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Source: Senate LDA
| DEXCOM INC |
| 28 |
| 2019–2025 |
| GREATER NEW YORK HOSPITAL ASSOCIATION | 28 | 2009–2020 |
| CELGENE CORPORATION | 27 | 2008–2014 |
| REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS | 27 | 2020–2026 |
| DEVOTED HEALTH | 26 | 2020–2026 |
| AMERICA'S HEALTH INSURANCE PLANS (AHIP) | 25 | 2020–2025 |
| COLORADO HOSPITAL ASSOCIATION | 25 | 2019–2026 |
| PARTNERSHIP FOR QUALITY HOME HEALTHCARE | 24 | 2019–2024 |
| NOVO NORDISK, INC. | 22 | 2009–2020 |
| TRAVERE THERAPEUTICS | 20 | 2019–2024 |
| EYECARE PARTNERS LLC | 18 | 2020–2024 |
| HEALTH MANAGEMENT ASSOCIATES | 17 | 2010–2014 |
| MARYLAND+COALITION | 17 | 2019–2023 |
| REHABILITATION INSTITUTE OF CHICAGO | 17 | 2010–2014 |
| SAFEWAY, INC. | 16 | 2009–2013 |
| TROUTMAN PEPPER STRATEGIES OBO CIVITAS NETWORKS FOR HEALTH (FKA SHIEC) | 14 | 2021–2024 |
| LANNETT COMPANY, INC. | 13 | 2009–2012 |
| FLOW THERAPY | 12 | 2019–2022 |
| FUTURE OF PHARMACY COALITION LLC | 12 | 2022–2025 |
| NATIONAL BRAIN TUMOR SOCIETY | 12 | 2024–2026 |
| DATAVANT INC. | 10 | 2024–2026 |
| TRIDENT USA HEALTH SERVICES | 10 | 2019–2021 |
| AMERICAN COLLEGE OF LIFESTYLE MEDICINE | 9 | 2019–2021 |
| BLUE SHIELD OF CALIFORNIA | 9 | 2024–2025 |
| CSL BEHRING LLC (FORMERLY ZLB BEHRING) | 9 | 2010–2012 |
| KERECIS | 9 | 2024–2026 |
| USAGAINSTALZHEIMER'S ACTION | 9 | 2021–2023 |
| CAREFUSION | 8 | 2009–2011 |
| CHE SENIOR PSYCHOLOGICAL SERVICES | 8 | 2019–2020 |
| EQUIFAX INC | 8 | 2025–2026 |
| MYLAN LABORATORIES | 8 | 2008–2011 |
| CHESAPEAKE REGIONAL INFORMATION SYSTEM FOR OUR PATIENTS (CRISP) | 7 | 2021–2022 |
| CLARITEV | 7 | 2025–2026 |
| WELVIE | 7 | 2019–2020 |
| CARESOURCE MISSION | 6 | 2025–2026 |
| CAROMONT HEALTH | 6 | 2010–2011 |
| COUNCIL OF STATE ADMINISTRATORS OF VOCATIONAL REHABILITATION ("CSAVR") | 6 | 2013–2014 |
| HEALTH SOUTH CORPORATION | 6 | 2009–2010 |
| PRUITTHEALTH PREMIER | 6 | 2020–2021 |
| BIOGEN, INC. | 5 | 2020 |
| HEALTHTRACKRX | 5 | 2025–2026 |
| MESA POWER GROUP | 5 | 2009 |
| OSSIUM HEALTH, INC. | 5 | 2025–2026 |
| OUTSET MEDICAL | 5 | 2023 |
| PROVIDER PARTNERS MANAGEMENT SERVICES, LLC | 5 | 2021–2022 |
| VERIZON COMMUNICATIONS | 5 | 2012–2013 |
| ACCESS TO PART B SERVICES FOR LTC RESIDENTS COALITION (INFORMAL COALITION) | 4 | 2024 |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 4 | 2019–2020 |
| COMMONWEALTH CARE ALLIANCE | 4 | 2024–2025 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION | 4 | 2011–2012 |
| ULTRASOUND ACCESS COALITION (UAC) (INFORMAL COALITION) | 4 | 2019 |
| LODGENET INTERACTIVE CORPORATION | 3 | 2011 |
| ONCOSEC MEDICAL INCORPORATED | 3 | 2020 |
| TENNESSEE HOSPITAL ASSOCIATION | 3 | 2008 |
| BROOKDALE SENIOR LIVING INC. | 2 | 2020 |
| HOSPITAL ASSOCIATION OF OREGON | 2 | 2025–2026 |
| NATIONAL GEOGRAPHIC EDUCATION FOUNDATION ("NGEF") | 2 | 2010 |
| NATIONAL SOCIETY OF AUTISM PROFESSIONALS | 2 | 2026 |
| PROSTRAKAN INC | 2 | 2008 |
| SCHILTZ FOODS, INC. | 2 | 2009 |
| TEMPUS LABS INC | 2 | 2023 |
| TIVITY HEALTH, INC. | 2 | 2024 |
| BRACCO DIAGNOSTICS INC. | 1 | 2007 |
| CHEYENNE INTERNATIONAL, LLC | 1 | 2007 |
| NATIONAL COORDINATING COMMITTEE FOR MULTIEMPLOYER PLANS | 1 | 2011 |
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors, including H.R.9113/S.4739, the BRAIN Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
To designate the facility of the United States Postal Service located at 220 North Hatcher Avenue in Purcellville, Virginia, as the "Secretary of State Madeleine Albright Post Office Building".
Client: USAGAINSTALZHEIMER'S ACTION · Firm: ALSTON & BIRD LLP
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
To designate the facility of the United States Postal Service located at 220 North Hatcher Avenue in Purcellville, Virginia, as the "Secretary of State Madeleine Albright Post Office Building".
Client: USAGAINSTALZHEIMER'S ACTION · Firm: ALSTON & BIRD LLP
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
To designate the facility of the United States Postal Service located at 220 North Hatcher Avenue in Purcellville, Virginia, as the "Secretary of State Madeleine Albright Post Office Building".
Client: USAGAINSTALZHEIMER'S ACTION · Firm: ALSTON & BIRD LLP
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Speeding Therapy Access Today Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Protecting Access to Post-COVID–19 Telehealth Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Speeding Therapy Access Today Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
Speeding Therapy Access Today Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act.
Speeding Therapy Access Today Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Speeding Therapy Access Today Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Speeding Therapy Access Today Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Consolidated Appropriations Act, 2023
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Issues related to increasing funding for Alzheimer's Research and improving strategies for early detection and prevention; family and medical leave; Advance Research Projects Agency-Health (ARPA-H); H.R. 3354, CHANGE Act; establishing a national Alzheimer's disease prevention goal.
Protecting Access to Post-COVID–19 Telehealth Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Protecting Access to Post-COVID–19 Telehealth Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.
Protecting Access to Post-COVID–19 Telehealth Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.
Protecting Access to Post-COVID–19 Telehealth Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases.
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
H.R.366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to Medicare Part B and Part D drug policies and access to therapies for patients with rare diseases.
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding drug pricing, value, and reimbursement; H.R. 3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R. 19, Lower Costs, More Cures Act of 2021; H.R. 1629, Fairness in Orphan Drug Exclusivity Act; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Accelerated Approval Integrity Act of 2022
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: FUTURE OF PHARMACY COALITION LLC · Firm: ALSTON & BIRD LLP
Advancing H.R.7213, Equitable Community Access to Pharmacist Services Act.
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 366, Protecting Access to Post-COVID-19 Telehealth Act and related legislation; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 5376 - Build Back Better Act, issues related to Medicare Part B and Part D drug policies.
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R.482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.2617, the Consolidated Appropriations Act, 2023.
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R. 1730/S.670, Speeding Therapy Access Today Act; H.R. 7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R. 6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes.
New Era of Preventing End-Stage Kidney Disease Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care; H.R. 482/S.350, Newborn Screening Saves Lives Act Reauthorization; H.R. 7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases.
Advancing contract and other partnership opportunities for Ossium.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
CLARITEV via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
CARESOURCE MISSION via ALSTON & BIRD LLP
2026 · third_quarter · Q3
Educating on general health insurance matters applicable to CareSource Mission.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OSSIUM HEALTH, INC. via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Advancing contract and other partnership opportunities for Ossium.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL SOCIETY OF AUTISM PROFESSIONALS via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Issues related to the reimbursement and credentialing of autism professionals.
Issues related to the reimbursement and credentialing of autism professionals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HOSPITAL ASSOCIATION OF OREGON via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B, site neutrality and Medicare Advantage.
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B, site neutrality and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
CVS HEALTH via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Issues related to Pub. L. No. 119-21, One Big Beautiful Bill Act, PBM reform and drug pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
COLORADO HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B and site neutrality payment reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLARITEV via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
CARESOURCE MISSION via ALSTON & BIRD LLP
2026 · second_quarter · Q2
Educating on general health insurance matters applicable to CareSource Mission.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL SOCIETY OF AUTISM PROFESSIONALS via ALSTON & BIRD LLP
2026 · second_quarter · RR
Issues related to the reimbursement and credentialing of autism professionals.
Issues related to the reimbursement and credentialing of autism professionals.
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OSSIUM HEALTH, INC. via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Advancing contract and other partnership opportunities for Ossium.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHTRACKRX via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Medicare and Medicaid laboratory reimbursement issues.
Medicare and Medicaid laboratory reimbursement issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
CVS HEALTH via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Issues related to Pub. L. No. 119-21, One Big Beautiful Bill Act, PBM reform and drug pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
COLORADO HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B and site neutrality payment reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLARITEV via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
CARESOURCE MISSION via ALSTON & BIRD LLP
2026 · first_quarter · Q1
Educating on general health insurance matters applicable to CareSource Mission.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
General health care issues related to Medicare coverage policies. FY2027 Appropriations Bill.
General health care issues related to Medicare coverage policies. FY2027 Appropriations Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2025 · first_quarter · 1A
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
OSSIUM HEALTH, INC. via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Advancing contract and other partnership opportunities for Ossium.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MASSACHUSETTS HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
General legislative and regulatory issues related to Medicare and Medicaid, including 340B, site neutrality payment reform, Medicare Advantage, Telehealth, and medical research indirect costs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Q4
General health care issues related to Medicare coverage policies.
General health care issues related to Medicare coverage policies.
HOSPITAL ASSOCIATION OF OREGON via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B, site neutrality and Medicare Advantage.
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B, site neutrality and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTHTRACKRX via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Medicare and Medicaid laboratory reimbursement issues.
Medicare and Medicaid laboratory reimbursement issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CVS HEALTH via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Issues related to Pub. L. No. 119-21, One Big Beautiful Bill Act, PBM reform and drug pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CLARITEV via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
CARESOURCE MISSION via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Educating on general health insurance matters applicable to CareSource Mission.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUE SHIELD OF CALIFORNIA via ALSTON & BIRD LLP
2025 · fourth_quarter · Q4
Health data interoperability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARESOURCE MISSION via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Educating on general health insurance matters applicable to CareSource Mission.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARESOURCE MISSION via ALSTON & BIRD LLP
2025 · third_quarter · RR
Educating on general health insurance matters applicable to CareSource Mission.
OSSIUM HEALTH, INC. via ALSTON & BIRD LLP
2025 · fourth_quarter · RR
Advancing contract and other partnership opportunities for Ossium.
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Q3
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Q3
General health care issues related to Medicare coverage policies.
General health care issues related to Medicare coverage policies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHTRACKRX via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Medicare and Medicaid laboratory reimbursement issues.
Medicare and Medicaid laboratory reimbursement issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Issues related to coverage and reimbursement for continuous glucose monitors.
Issues related to coverage and reimbursement for continuous glucose monitors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CVS HEALTH via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Issues related to Pub. L. No. 119-21, One Big Beautiful Bill Act, PBM reform and drug pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CLARITEV via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
BLUE SHIELD OF CALIFORNIA via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Health data interoperability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICA'S HEALTH INSURANCE PLANS (AHIP) via ALSTON & BIRD LLP
2025 · third_quarter · Q3
Issues related to the health insurance industry.
Issues related to the health insurance industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Q2
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Cost plan matters; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · second_quarter · Q2
General health care issues related to Medicare coverage policies.
General health care issues related to Medicare coverage policies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHTRACKRX via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Medicare and Medicaid laboratory reimbursement issues.
Medicare and Medicaid laboratory reimbursement issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION LLC via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Advance the Ensuring Access to Pharmacist Services Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Issues related to coverage and reimbursement for continuous glucose monitors.
Issues related to coverage and reimbursement for continuous glucose monitors.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CVS HEALTH via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Issues related to the implementation of health care reform and issues related to PBMs and drug pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
COMMONWEALTH CARE ALLIANCE via ALSTON & BIRD LLP
2025 · second_quarter · 2T
Educating on dual eligible health insurance matters applicable to the Commonwealth Care Alliance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COLORADO HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B and site neutrality payment reforms.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CLARITEV via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
BLUE SHIELD OF CALIFORNIA via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Health data interoperability. Medicaid financing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICA'S HEALTH INSURANCE PLANS (AHIP) via ALSTON & BIRD LLP
2025 · second_quarter · Q2
Issues related to the health insurance industry.
Issues related to the health insurance industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHTRACKRX via ALSTON & BIRD LLP
2025 · second_quarter · RR
Medicare and Medicaid laboratory reimbursement issues.
Medicare and Medicaid laboratory reimbursement issues.
CLARITEV via ALSTON & BIRD LLP
2025 · second_quarter · RR
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
Issues related to healthcare reimbursement; issues related to payment and revenue integrity.
REDWOOD HOLDINGS, LLC FKA REDWOOD CAPITAL INVESTMENTS via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Medicare Advantage issues; Health Care Reimbursement; Home health long-term care issues as it relates to health care reform implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL BRAIN TUMOR SOCIETY via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Lobbying related to support and introduction of legislation to promote awareness of, research on and treatment of brain tumors.
Filing targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2025 · first_quarter · Q1
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · first_quarter · Q1
General health care issues related to Medicare coverage policies.
General health care issues related to Medicare coverage policies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FUTURE OF PHARMACY COALITION LLC via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Advancing equitable community access to pharmacist services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EQUIFAX INC. via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Advocacy and guidance on Medicare, Medicaid, and Social Security issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Issues related to coverage and reimbursement for continuous glucose monitor.
Issues related to coverage and reimbursement for continuous glucose monitor.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEVOTED HEALTH via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Issues related to Medicare Advantage Health Plan.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DATAVANT INC. via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Information sharing across the health care ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS HEALTH via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Issues related to the implementation of health care reform and issues related to PBMs and drug pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
COMMONWEALTH CARE ALLIANCE via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Educating on dual eligible health insurance matters applicable to the Commonwealth Care Alliance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COLORADO HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Hospital issues, including Medicare and Medicaid-related hospital issues, including 340B and site neutrality payment reforms.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BLUE SHIELD OF CALIFORNIA via ALSTON & BIRD LLP
2025 · first_quarter · Q1
Health data interoperability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE